Search company, investor...
Search
Tessa Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

tessacell.com

Founded Year

2001

Stage

Series A | Alive

Total Raised

$256M

Last Raised

$126M | 4 mos ago

Mosaic Score

+130 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Tessa Therapeutics

Tessa Therapeutics is a clinical-stage biotechnology company developing cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma (Phase 2). TT11 has been granted RMAT designation by the FDA and PRIME designation by European Medicine Agency. Tessa is also advancing an allogeneic “off-the shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa Therapeutics was founded in 2001 and is based in Singapore.

Tessa Therapeutics Headquarters Location

8 Temasek Boulevard #24-02 Suntec Tower 3

038988,

Singapore

+65 6384 0755

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Tessa Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tessa Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Tessa Therapeutics Patents

Tessa Therapeutics has filed 10 patents.

The 3 most popular patent topics include:

  • Immune system
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2017

7/9/2019

Clusters of differentiation, Immunology, Immune system, Transcription factors, Oncology

Grant

Application Date

5/12/2017

Grant Date

7/9/2019

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Oncology

Status

Grant

Latest Tessa Therapeutics News

General : Tessa recognised in “Most Promising Off-the-Shelf Therapies” category at ACGTEA 2022

Sep 15, 2022

Tessa recognised in “Most Promising Off-the-Shelf Therapies” category at ACGTEA 2022 15/09/2022 05:26 PM KUALA LUMPUR, Sept 15 (Bernama) -- Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company, has announced that TT11X, the company’s allogeneic “off-the-shelf” CD30.CAR EBVST cell therapy, has been recognised in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022. According to a statement, the ACGTEA 2022 Awards were held in conjunction with the 6th Cell & Gene Therapy World Asia 2022. “We are very excited to be recognised among the innovators in developing ‘off-the-shelf’ cell therapy technologies and greatly appreciate the ACGTEA 2022 award,” said Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics, Dr Ivan Horak. “Allogeneic cell therapy technology has the potential to transform the accessibility and affordability of CAR-T, but toxicity concerns remain a key obstacle. “Data from our ongoing Phase 1 trial of TT11X suggest that our CD30.CAR EBVST platform has the potential to overcome these toxicity challenges, including GVHD, while also eliciting promising signals of efficacy.” TT11X is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform. This technology was developed following decades-long research by the company’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and researchers at Baylor College of Medicine, into the unique properties of virus specific T-cells (VSTs). These highly specialised T cells have the ability to recognise and kill infected cells while activating other parts of the immune system for a coordinated response. Allogeneic VSTs without any form of genetic modification have demonstrated a strong safety profile and efficacy in early trials with minimal risk of graft rejection and Graft vs Host Disease (GVHD). More details at www.tessacell.com . -- BERNAMA Bernama is the trusted source of reliable real-time comprehensive and accurate news for both the public and media practitioners. Our news is published at www.bernama.com ; BERNAMA TV on: Astro Channel 502, unifi TV Channel 631, MYTV Channel 121 IFLIX; and Bernama Radio broadcasting locally on FM93.9 in Klang Valley, Johor (FM107.5), Kota Kinabalu (FM107.9) and Kuching (FM100.9). Follow us on social media : Facebook : @bernamaofficial, @bernamatv, @bernamaradio

Tessa Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Tessa Therapeutics Rank

  • When was Tessa Therapeutics founded?

    Tessa Therapeutics was founded in 2001.

  • What is Tessa Therapeutics's latest funding round?

    Tessa Therapeutics's latest funding round is Series A.

  • How much did Tessa Therapeutics raise?

    Tessa Therapeutics raised a total of $256M.

  • Who are the investors of Tessa Therapeutics?

    Investors of Tessa Therapeutics include Heritas Capital, Temasek, EDBI, Heliconia Capital Management, Polaris Partners and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.